Trial
NCT02376972
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Alfasigma S.p.A.
Collaborators
Parexel
Condition
BACTERIAL VAGINOSIS
Intervention
RIFAXIMIN VAGINAL TABLET 25 MG
Why stopped
According to the Recommendation of the Indipendent Data Monitoring Committee
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-10